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too restrictive a parameter. Indeed, severe SOS can be ident-
ified macroscopically (Figure 1) or histologically in preopera-
tive frozen sections. By making the surgeon aware of this
lesion, a large resection can be avoided or more extensive por-
tal embolisation can be used before surgery to reduce the risk
of post-operative liver failure.
Since the recent publication of our paper we have become
aware of several cases of patients developing complications
(with long hospitalisations in intensive care unit) because of
the delay in liver regeneration and liver insufficiency after
limited hepatectomy (unpublished data). A patient has devel-
oped acute fatal portal hypertension after oxaliplatin-based
adjuvant chemotherapy for colorectal carcinoma [2]. The pub-
lication of such observations in the near future will support
the concept that SOS is a real and relevant clinical entity in
oxaliplatin-based chemotherapy.
In our experience, oxaliplatin is a very useful drug that
yields excellent responses in hepatic colorectal metastases,
and we believe that its use will continue to increase. There-
fore, far from intending to question the efficacy of oxaliplatin
in the treatment of colorectal metastasis, we suggest that the
occurrence of clinically significant secondary effects on the
liver need to be recognised to increase the safety of liver sur-
gery. The scope of these observations may further expand as
oxaliplatin is becoming used as adjuvant therapy in the treat-
ment of several other malignancies.
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Obesity may decrease the
amenorrhea associated with
chemotherapy in premenopausal
breast cancer patients
We read with great interest the article by Berclaz et al. [1],
which stated that body mass index (BMI) is an independent
prognostic factor for overall survival in patients with breast
cancer, especially among pre-/perimenopausal patients treated
with chemotherapy without endocrine therapy. These authors
proposed different explanations for this association. We would
like to mention another explanation.
Amenorrhea is also an important prognostic factor for pre-
dicting the efficacy of chemotherapy in premenopausal
patients [2]. It is known that obese women have a longer
reproductive life and that longer exposure to estrogen
increases breast cancer risk. Although there were insufficient
data to demonstrate that chemotherapy is associated with a
decreased incidence of amenorrhea in obese patients compared
with lean counterparts, Mehta et al. [3] showed that 71% of
obese patients develop amenorrhea after receiving chemother-
apy, compared with 80% of non-obese breast cancer patients.
In light of the above information, we propose that obesity
itself, by suppressing the amenorrhea associated with che-
motherapy, may result in poorer prognosis in premenopausal
breast cancer patients with a high BMI.
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Reply to the Letter to the Editor
on “Obesity may decrease the
amenorrhea associated with
chemotherapy in premenopausal
breast cancer patients”, by
K. Altundag et al. (Ann Oncol
2005; 16: 333)
Altundag and colleagues suggest that obese women have an
increased breast cancer risk due to a longer reproductive life.
A meta-analysis of 23 studies providing information on
body mass index incidence in premenopausal breast cancer
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has shown an inverse association between obesity and breast
cancer [1]. These results have been confirmed in the large US
female nurses cohort [2].
In a prospective evaluation about relative weight on the
occurrence of natural menopause, no association could be
demonstrated between obesity and a delayed menopause [3].
We agree with Altundag and colleagues that the role of
obesity in the development of amenorrhea after chemotherapy
needs to be evaluated in larger studies as in the quoted publi-
cation of Mehta et al. [4], in which the number of patients [37
of 46 (80%) non-obese and 17 of 24 (71%) obese women
became amenorrheic] was much too small to draw any con-
clusions (P = 0.84).
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Intra-arterial hepatic
chemotherapy in heavily
pretreated patients with epithelial
ovarian cancer
Ovarian cancer is the fifth leading cause of cancer-related
death among women, and is the most lethal of the gynaecolo-
gic malignancies [1, 2]. The standard first-line treatment is
cytoreductive surgery and combination chemotherapy [3].
Relapsed ovarian cancer is generally incurable and patients
who relapse will die of their disease. The most common site
of recurrence is the peritoneal cavity, while liver metastases
are very rare. Patients who develop liver involvement often
have refractory disease to systemic chemotherapy and carry a
very poor prognosis [4].
Systemic melphalan has been widely used, from oral admin-
istration to high-dose chemotherapy, in a strategy of blood
and marrow transplantation [5, 6]. The intra-arterial route is
not documented. From March 2002 to December 2003, four
patients with histologically confirmed liver metastases and
peritoneal involvement from ovarian cancer entered this study.
Median liver involvement was more than 50% and ascites was
observed in three patients. All patients had platinum-resistant
disease and they progressed after systemic chemotherapy with
taxanes, topotecan and pegylated liposomal doxorubicin. The
median age was 53 years; performance status (WHO criteria)
was 2 in one patient and 1 in three. Abdominal pain was pre-
sent in all patients, with a median visual analogue scale
(VAS) value of 5.3. In three patients, CA125 level was high
(median 12.5 U/ml).
Melphalan was infused bolus by angiographic catheter
introduced in the proper hepatic artery using the Seldinger
technique at a dosage of 20 mg/m2 on day 1, every 4 weeks;
after each administration the CA125 catheter was removed.
The response was evaluated according to WHO criteria and
toxicity was graded according to the National Cancer Institute
Common Toxicity Criteria.
Fifteen cycles were administered; no side-effects related to
the angiographic procedure were observed. Mild haematologi-
cal toxicity occurred: one case of grade 3 leukopaenia and one
case of grade 3 thrombocytopaenia were observed. Three
patients showed a reduction of liver metastases of more than
50%, but one showed disease progression after one cycle. In
two patients we observed a significant reduction of ascites and
an impressive reduction in CA125 level in the other two
cases. The responders showed an improvement in performance
status and a marked pain reduction (median VAS of 2.3).
After a median follow-up of 15 months (range 5–21) three
patients were dead, with a median survival of 13 months from
intra-arterial chemotherapy. The time taken to respond to che-
motherapy was 3 weeks and the time taken to ascertain failure
of the treatment was 4.5 months. The live patient is a respon-
der and showed a liver and pleural progression of the disease
after 5 months.
This novel therapeutic approach appears very well tolerated
and feasible in heavily pretreated patients with liver metas-
tases from platinum-resistant epithelial ovarian cancer. This
approach showed an interesting activity and a significantly
rapid clinical improvement.
Further studies are warranted to verify these preliminary
results.
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